Morgan Stanley’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.57M | Buy |
570,450
+148,360
| +35% | +$669K | ﹤0.01% | 4548 |
|
|
2025
Q1 | $1.96M | Sell |
422,090
-1,833,263
| -81% | -$8.51M | ﹤0.01% | 4613 |
|
|
2024
Q4 | $15.7M | Buy |
2,255,353
+2,130,021
| +1,700% | +$14.8M | ﹤0.01% | 2996 |
|
|
2024
Q3 | $664K | Buy |
125,332
+56,990
| +83% | +$302K | ﹤0.01% | 5263 |
|
|
2024
Q2 | $256K | Buy |
68,342
+12,612
| +23% | +$47.2K | ﹤0.01% | 5570 |
|
|
2024
Q1 | $393K | Sell |
55,730
-107,222
| -66% | -$756K | ﹤0.01% | 5418 |
|
|
2023
Q4 | $921K | Buy |
162,952
+126,886
| +352% | +$717K | ﹤0.01% | 5329 |
|
|
2023
Q3 | $173K | Sell |
36,066
-15,014
| -29% | -$71.9K | ﹤0.01% | 5648 |
|
|
2023
Q2 | $350K | Buy |
51,080
+12,850
| +34% | +$88K | ﹤0.01% | 5395 |
|
|
2023
Q1 | $298K | Sell |
38,230
-69,467
| -65% | -$541K | ﹤0.01% | 5518 |
|
|
2022
Q4 | $820K | Sell |
107,697
-14,426
| -12% | -$110K | ﹤0.01% | 4972 |
|
|
2022
Q3 | $996K | Sell |
122,123
-17,526
| -13% | -$143K | ﹤0.01% | 4882 |
|
|
2022
Q2 | $1.35M | Buy |
139,649
+4,970
| +4% | +$48K | ﹤0.01% | 4817 |
|
|
2022
Q1 | $1.89M | Sell |
134,679
-1,260
| -0.9% | -$17.7K | ﹤0.01% | 4555 |
|
|
2021
Q4 | $2.78M | Buy |
135,939
+42,038
| +45% | +$858K | ﹤0.01% | 4302 |
|
|
2021
Q3 | $2.09M | Buy |
+93,901
| New | +$2.09M | ﹤0.01% | 4531 |
|